EMA Committee Recommends Marketing Authorisation for Biocon's Pertuzumab Biosimilar
Biocon Biologics' Pertuzumab biosimilar, branded as Pebrilzo, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for treating HER2-positive breast cancer across multiple stages. This marks the first monoclonal antibody biosimilar approved under EMA's tailored clinical development approach. The European Commission will now review the application for final approval. Until then, Pebrilzo is not authorised for use in the European Union.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (64/100). Lens Score 47/100.
Outlets measured: businessstandard, businessstandard, businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (58–72/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 21 Sept, 04:10 am. Other outlets followed.